BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
BC Innovations | Sep 27, 2019
Emerging Company Profile

Chain: engineering microbial delivery to the colon

Chain Biotechnology’s engineered Clostridium -based therapies that are administered as dose-adjustable bacterial spores could offer more targeted delivery to the colon than other microbial therapies. “Most microbial activity in the GI tract occurs in the...
BC Extra | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
BC Innovations | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
BC Week In Review | Apr 19, 2019
Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
BC Week In Review | Dec 21, 2018
Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
BC Extra | Dec 20, 2018
Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
BC Innovations | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
BC Extra | Aug 14, 2018
Company News

Management tracks: Cheng departing Gilead as CMO

Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after five months in the role to pursue another opportunity. Gilead did not say who would replace Cheng, who joined...
Items per page:
1 - 10 of 241
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
BC Innovations | Sep 27, 2019
Emerging Company Profile

Chain: engineering microbial delivery to the colon

Chain Biotechnology’s engineered Clostridium -based therapies that are administered as dose-adjustable bacterial spores could offer more targeted delivery to the colon than other microbial therapies. “Most microbial activity in the GI tract occurs in the...
BC Extra | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
BC Innovations | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
BC Week In Review | Apr 19, 2019
Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...
BC Week In Review | Dec 21, 2018
Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
BC Extra | Dec 20, 2018
Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
BC Innovations | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
BC Extra | Aug 14, 2018
Company News

Management tracks: Cheng departing Gilead as CMO

Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after five months in the role to pursue another opportunity. Gilead did not say who would replace Cheng, who joined...
Items per page:
1 - 10 of 241